Evidence map›Paper›PMID 36713761›Full record

ArticleJACC. Asia2022

Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.

Masanobu Ishii, Koichi Kaikita, Satoshi Yasuda, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02642419 (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02642419 phase4unknown statusnot on this map

Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)

TypeinterventionalSponsorJapan Cardiovascular Research FoundationRan2015 to 2017Enrolled2,200ConditionsAtrial FibrillationArmsRivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel), Rivaroxaban
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Masanobu IshiiDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Koichi KaikitaDivision of Cardiovascular Medicine and Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan.
Satoshi YasudaDepartment of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Masaharu AkaoDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Tetsuya MatobaDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.
Masato NakamuraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan.
Katsumi MiyauchiDepartment of Cardiovascular Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Koto-ku, Tokyo, Japan.
Nobuhisa HagiwaraDepartment of Cardiology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Kazuo KimuraCardiovascular Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Atsushi HirayamaDepartment of Cardiology, Osaka Police Hospital, Osaka, Osaka, Japan.
Kunihiko MatsuiDepartment of General Medicine and Primary Care, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan.
Hisao OgawaKumamoto University, Kumamoto, Kumamoto, Japan.
Kenichi TsujitaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
AFIRE Investigators
Kumamoto University · JPKitasato University · JPKoto Hospital · JPKumamoto University Hospital · JPKyoto Medical Center · JPKyushu University · JPOsaka Police Hospital · JPTohoku University · JPToho University · JPTokyo Women's Medical University · JPUniversity of Miyazaki · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial showed both noninferiority for efficacy and superiority for safety endpoints of rivaroxaban monotherapy compared with those of rivaroxaban plus antiplatelet therapy (combination therapy) in patients with atrial fibrillation and stable coronary artery disease. Objectives: This study sought to evaluate outcomes of rivaroxaban monotherapy in those patients across body mass index (BMI) categories. Methods: Patients were categorized into 4 groups: underweight (BMI <18.5 kg/m Results: This study analyzed 2,054 patients with a median age of 75.0 years and CHA Conclusions: Rivaroxaban monotherapy had a similar effect on prognosis across all BMI categories in patients with atrial fibrillation and stable coronary artery disease. (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease [AFIRE]; UMIN000016612, NCT02642419).

Indexed as

AF, atrial fibrillationatrial fibrillationBMI, body mass indexCAD, coronary artery diseasecoronary artery diseaseDOAC, direct oral anticoagulantsMACCE, major adverse cardiac and cerebral event(s)NACE, net adverse clinical event(s)obeseunderweight

Identifiers

PMID36713761
PMCPMC9876995
OpenAlexW4293321663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.